Program
aletekitug
Also written as “GSK1070806”, “Aletekitug” and “Aletekitug (GSK1070806)”.
Its studies are mostly in Dermatitis, Atopic · Colitis, Ulcerative · Delayed Graft Function · Inflammatory Bowel Diseases · Diabetes Mellitus, led by GlaxoSmithKline.
Furthest: phase 2, since Jul 12, 20129 company-led studies, 2 open or runningNext primary completion: Mar 5, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 92 open or running | phase 2since Jul 12, 2012 | Dec 17, 2009 | Mar 5, 2028phase 1 · NCT07747480 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2009First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT01035645 · 78 enrolled · United Kingdom
- Jul 12, 2012Phase 2 study in Diabetes MellitusNCT01648153 · 37 enrolled · Spain, United Kingdom
- Mar 14, 2016Phase 2 study in Delayed Graft FunctionNCT02723786 · 7 enrolled · Spain, United Kingdom
- Jul 14, 2021Phase 1 study in Dermatitis, AtopicNCT04975438 · 34 enrolled · United States, Canada
- Oct 18, 2022Phase 1 study in Dermatitis, AtopicNCT05590338 · 38 enrolled · United States
- Aug 11, 2023Phase 2 study in Dermatitis, AtopicNCT05999799 · 161 enrolled · United States, Argentina, Bulgaria and more
- Jun 3, 2024Phase 2 study in Dermatitis, AtopicNCT06447506 · 79 enrolled · United States, Argentina, Bulgaria and more
- Jul 31, 20262 phase 1 studies in Colitis, UlcerativeNCT07747480, NCT07747467
- Oct 28, 2026Primary completion moved from 2028-07-31 to 2029-03-21Date moved laterphase 1 · +8 months · NCT07747467
Ahead
- Mar 5, 2028Primary completion: phase 1 study in Colitis, UlcerativeNCT07747480
- Mar 21, 2029Primary completion: phase 1 study in Colitis, UlcerativeNCT07747467
TargetBeta
IL18 →read by rule
“Interleukin-18 inhibitor”ChEMBL 37, by rule
Other programs on IL18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| arumakimig | Novartis | phase 2 | 7 |
| camoteskimabrule | apollo-therapeutics-ltd | phase 2 | 5 |
| GHZ339 | Novartis | phase 2 | 1 |
| BLN-481rule | beeline-medicines-corporation | phase 1 | 1 |
| GSK4528287 | GlaxoSmithKline | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07747480Colitis, Ulcerative · United Kingdom | 1 | Recruiting | Mar 5, 2028 | 16 |
| NCT07747467Colitis, Ulcerative · United Kingdom | 1 | Recruiting | Mar 21, 2029 | 8 |
| NCT06447506Dermatitis, Atopic · United States, Argentina, Bulgaria and more | 2 | Terminated | Jul 29, 2025 | 79 |
| NCT05999799Dermatitis, Atopic · United States, Argentina, Bulgaria and more | 2 | Terminated | Jul 23, 2025 | 161 |
| NCT05590338Dermatitis, Atopic · United States | 1 | Completed | Jul 12, 2023 | 38 |
| NCT04975438Dermatitis, Atopic · United States, Canada | 1 | Completed | Dec 19, 2022 | 34 |
| NCT02723786Delayed Graft Function · Spain, United Kingdom | 2 | Terminated | Mar 31, 2017 | 7 |
| NCT01648153Diabetes Mellitus · Spain, United Kingdom | 2 | Completed | Sep 2013 | 37 |
| NCT01035645Inflammatory Bowel Diseases · United Kingdom | 1 | Completed | Jul 11, 2012 | 78 |
How it is read
Names in the registry
- “GSK1070806”, 8 entries
- “Aletekitug”, 1 entry
- “Aletekitug (GSK1070806)”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 4 studies
- Colitis, Ulcerative, 2 studies
- Delayed Graft Function, 1 study
- Inflammatory Bowel Diseases, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.